Patrick Doyle

Selected for this role to enhance regional performance by developing and overseeing execution of the strategic commercial plan. Leveraging 20+ years of commercial leadership experience, I developed and executed the regional marketing and commercial strategic plan to deliver $1.7B annual revenues and ~$1B IBT across the Latin America-Canada region. I direct a team of ~43 colleagues across the U.S. and Latin America that includes 9 direct reports. HIGHLIGHTS: ☑ Drove breakthrough 9% organic growth in regional business and 101% of annual revenue forecast for a portfolio of established brands (growth 2nd only to China among all emerging markets within Pfizer). ☑ Achieved 7% growth in 2017 and 14% growth in 2018 for the Hospital Channel through launching “Key Account Management” go-to market model in Latin America to optimize performance of emerging hospital portfolio. ☑ Increased field force productivity ~15% by leading a regional field force effectiveness project that optimized customer segmentation, products promoted, sample utilization, KPI reporting/dashboard analytics, and enhanced representative analytical capabilities. ☑ Spearheaded 4 organic product launches in 2018, surpassing target launch dates by ~3 months, through directing team in accelerated registration, pre-launch, and go-to market activities. ☑ Contributed to projected ~$100M in incremental revenues by 2020 through role in successful acquisition and integration of Astra-Zeneca’s Anti-Infective portfolio for Latin America. ☑ Achieved 49%, region-wide customer reach by mid-2018 through leading the development and launch of an omni-channel digital strategy. Additional benefits included CTR and cost-per-click outperforming global benchmarks as well as a significantly higher market share growth with key customer segments.

I was promoted to lead the launch of a new Women’s Health Business Unit with a $1B+ revenue target. Reporting to the Global President, I led a team of 300+ that included 8 direct reports (incl. 5 Brand Leads and 2 Sales VPs). In this position, I was heavily involved in team building and leadership initiatives. I guided Women’s Health marketing teams in implementing high-impact strategies that fulfilled revenue, IBT, and expense goals. I collaborated with the U.S. Brands leadership team to align our Women’s Health portfolio with the broader organizational objectives. And I launched and managed a PEH U.S. Women’s Health sales team in delivering against portfolio sales goals. HIGHLIGHTS: ☑ Delivered 105% of $1B revenue budget in FY 2016 (vs. 97% attainment in previous year from prior leader) through executive effective strategic plan and building/leading a top-performing team. ☑ Launched Women’s Health field force of ~260 that served as a key driver of revenue and IBT success, with a focus on 3 key areas: Colleague Engagement, Training & Enablement, and Optimized Resourcing, with ROI increasing from 0.9:1 to 1.4:1 in 2016. ☑ Facilitated several key breakthrough initiatives by focusing team on commercial innovation, including Digital Rep Advisor, Personalized Digital Marketing, New Digital/TV Consumer Campaign, and an online Women’s Health “Concierge Hub” with “Nurse Chat” function that focused on patient experience/education/retention. ☑ Improved internal culture and engagement scores, despite near-50% reduction in field force size, through implementation of “People First, Performance Always” leadership philosophy

I was promoted to oversee a ~$1.5B portfolio comprised of Celebrex, the #1 branded Rx business within its class (~$1B), and Pristiq, the #1 branded SNRI for depression (~$500M). Directing and coaching a team of 10 marketing leaders, I created a wide range of strategic plans that included marketing and operational initiatives. HIGHLIGHTS: ☑ Achieved 100+% of financial goals for Pristiq in each of 3 consecutive years, including 105% of revenue and 101% of IBT for 2013, 108% of revenue and 107% of IBT for 2014, and 108% of revenue and 106% of IBT for 2015. ☑ Influenced ELT/BU President to invest incremental $55M in Pristiq for FY 2014 by sustaining field force and high-ROI consumer campaigns. Created business case and operating plan that were endorsed by the BU President and implemented to deliver incremental ~$750M over Long-Range Forecast. ☑ Executed successful plan for 2nd-largest LOE in Pfizer’s history (multibillion-dollar Celebrex). Launched innovative HCP and consumer marketing plans to surpass LOE share loss curves by ~15%, exceeding 2016 budget.

Within a heavily competitive process, I was selected for a Mid-Atlantic regional leadership role as Pfizer was launching a new RBU structure and selecting 13 RBDs to lead the U.S. business. Leading a team of 19, I reported directly to the Regional President. HIGHLIGHTS: ☑ Delivered 99% of revenue attainment in 2012 and 103% in 2013 following launch of new organization, including personal selection of all 8 LT members. Facilitated successful launch of Key Account Management model within the region and delivered multiple unique customer projects that drove value for Pfizer and its customers. ☑ Assisted in driving legislative action to support improved patient care and open access for Pfizer meds (e.g. standardized electronic prior authorization form in PA, pain therapy step-through bill to minimize patient failure on initial treatments).